The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC

Raymond Wadlow, MD
Published Online:4:01 PM, Mon February 4, 2019


Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses results from the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer (CRC).

During a presentation at the 2019 Gastrointestinal Cancers Symposium, an overall survival benefit of approximately 2.5 months was found in patients with microsatellite-stable CRC.

This is exciting as it is the first finding, according to Wadlow, that shows a statistically significant improvement with a checkpoint inhibitor in the majority of this patient population.

See more from the 2019 Gastrointestinal Cancers Symposium.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.